CLOs on the Move

ColoWrap

www.colowrap.com

 
ColoWrap is the first clinical colonoscopy compression device that prevents the need for manual abdominal pressure and patient repositioning during colonoscopy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.colowrap.com
  • 413, W Cornwallis Rd
    Durham, NC USA 27707
  • Phone: 919.451.1803

Executives

Name Title Contact Details

Similar Companies

Physician Partner

Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UltraFiltronics Corp

UltraFiltronics Corp is a Randolph, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DMD Pharmaceuticals

DMD Pharmaceuticals is a Noblesville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novo Nordisk

At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Diabetes poses one of today`s biggest global health challenges. We work for a future where fewer people get diabetes, everyone with diabetes is diagnosed, and everyone who is diagnosed receives adequate treatment and can live a life with as few limitations as possible. Since the company was founded in Denmark more than 90 years ago, we have been changing diabetes. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done. This page isn`t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.

Intercept Pharmaceuticals

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.